Gln27 arrow right Glu beta 2-Adrenergic Receptor Polymorphism in Heart Failure Patients: Differential Clinical and Oxidative Response to Carvedilol

We investigated the clinical response of chronic heart failure patients with beta 2-adrenergic receptor Gln27 arrow right Glu polymorphism treated for 6 months with carvedilol, a alpha / beta -antagonist with antioxidant properties. The 6-min. walk test, the left ventricular ejection fraction, heart...

Full description

Saved in:
Bibliographic Details
Published in:Basic & clinical pharmacology & toxicology 2009-05, Vol.104 (5), p.374-378
Main Authors: Troncoso, Rodrigo, Moraga, Francisco, Chiong, Mario, Roldan, Juan, Bravo, Roberto, Valenzuela, Rodrigo, Diaz-Araya, Guillermo, del Campo, Andrea, Sanhueza, Carlos, Rodriguez, Andrea, Vukasovic, Jose Luis, Mellado, Rosemarie, Greig, Douglas, Castro, Pablo F, Lavandero, Sergio
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We investigated the clinical response of chronic heart failure patients with beta 2-adrenergic receptor Gln27 arrow right Glu polymorphism treated for 6 months with carvedilol, a alpha / beta -antagonist with antioxidant properties. The 6-min. walk test, the left ventricular ejection fraction, heart rate, plasma norepinephrine and malondialdehyde, a stress oxidative marker, concentrations were evaluated at baseline and after treatment for 6 months with carvedilol in 33 stable chronic heart failure patients with the Gln27 arrow right Glu beta 2-adrenergic receptor polymorphism. Carvedilol significantly increased the left ventricular ejection fraction, while decreasing the heart rate and malondialdehyde plasma concentrations in chronic heart failure patients with the Glu27 beta 2-adrenergic receptor allele. There were however, no significant changes in patients with the Gln27 beta 2-adrenergic receptor variant.
ISSN:1742-7835
1742-7843
DOI:10.1111/j.1742-7843.2008.00370.x